Literature DB >> 29674323

Hemoglobin A1c Accurately Predicts Continuous Glucose Monitoring-Derived Average Glucose in Youth and Young Adults With Cystic Fibrosis.

Christine L Chan1, Emma Hope2, Jessica Thurston2,3, Timothy Vigers2, Laura Pyle2,3, Philip S Zeitler2, Kristen J Nadeau2.   

Abstract

OBJECTIVE: In cystic fibrosis (CF), hemoglobin A1c (HbA1c) is thought to underestimate glycemia. However, few studies have directly assessed the relationship between HbA1c and average glucose in CF. We determined the relationships among glycemic markers-HbA1c, fructosamine (FA), glycated albumin (%GA), and 1,5-anhydroglucitol (1,5-AG)-and continuous glucose monitoring (CGM) in CF, hypothesizing that alternate markers would better predict average sensor glucose (ASG) than HbA1c. RESEARCH DESIGN AND METHODS: CF participants and a group of healthy control subjects (HCs), ages 6-25 years, wore CGM for up to 7 days. Pearson correlations assessed the relationships between CGM variables and HbA1c, FA, %GA, and 1,5-AG. The regression line between HbA1c and ASG was compared in CF versus HC. Linear regressions determined whether alternate markers predicted ASG after adjustment for HbA1c.
RESULTS: CF (n = 93) and HC (n = 29) groups wore CGM for 5.2 ± 1 days. CF participants were 14 ± 3 years of age and 47% were male, with a BMI z score -0.1 ± 0.8 and no different from HCs in age, sex, or BMI. Mean HbA1c in CF was 5.7 ± 0.8% (39 ± 9 mmol/mol) vs. HC 5.1 ± 0.2% (32 ± 2 mmol/mol) (P < 0.0001). All glycemic markers correlated with ASG (P ≤ 0.01): HbA1c (r = 0.86), FA (r = 0.69), %GA (r = 0.83), and 1,5-AG (r = -0.26). The regression line between ASG and HbA1c did not differ in CF versus HC (P = 0.44). After adjustment for HbA1c, %GA continued to predict ASG (P = 0.0009) in CF.
CONCLUSIONS: HbA1c does not underestimate ASG in CF as previously assumed. No alternate glycemic marker correlated more strongly with ASG than HbA1c. %GA shows strong correlation with ASG and added to the prediction of ASG beyond HbA1c. However, we are not advocating use of HbA1c for diabetes screening in CF based on these results. Further study will determine whether glycemic measures other than ASG differ among different types of diabetes for a given HbA1c.
© 2018 by the American Diabetes Association.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29674323      PMCID: PMC6014540          DOI: 10.2337/dc17-2419

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  37 in total

1.  HbA1c is not recommended as a screening test for diabetes in cystic fibrosis.

Authors:  R W Holl; C Buck; C Babka; A Wolf; A Thon
Journal:  Diabetes Care       Date:  2000-01       Impact factor: 19.112

2.  Relationship between glycosylated haemoglobin and mean plasma glucose concentration in cystic fibrosis.

Authors:  Amanda L Brennan; Khin M Gyi; David M Wood; Margaret E Hodson; Duncan M Geddes; Emma H Baker
Journal:  J Cyst Fibros       Date:  2005-09-30       Impact factor: 5.482

3.  Screening for type 2 diabetes and prediabetes in obese youth: evaluating alternate markers of glycemia - 1,5-anhydroglucitol, fructosamine, and glycated albumin.

Authors:  Christine L Chan; Laura Pyle; Megan Kelsey; Lindsey Newnes; Philip S Zeitler; Kristen J Nadeau
Journal:  Pediatr Diabetes       Date:  2015-02-05       Impact factor: 4.866

4.  1,5-anhydroglucitol and postprandial hyperglycemia as measured by continuous glucose monitoring system in moderately controlled patients with diabetes.

Authors:  Kathleen M Dungan; John B Buse; Joseph Largay; Mary M Kelly; Eric A Button; Shuhei Kato; Steven Wittlin
Journal:  Diabetes Care       Date:  2006-06       Impact factor: 19.112

5.  Correlation between 1,5-anhydroglucitol and glycemic excursions in type 2 diabetic patients.

Authors:  Jie Sun; Jing-Tao Dou; Xian-Ling Wang; Guo-Qing Yang; Zhao-Hui Lü; Hua Zheng; Fang-Ling Ma; Ju-Ming Lu; Yi-Ming Mu
Journal:  Chin Med J (Engl)       Date:  2011-11       Impact factor: 2.628

6.  Glucose tolerance and insulin secretion, morbidity, and death in patients with cystic fibrosis.

Authors:  Elise Bismuth; Kathleen Laborde; Pierre Taupin; Gilberto Velho; Virginie Ribault; Farida Jennane; Etienne Grasset; Isabelle Sermet; Jacques de Blic; Gérard Lenoir; Jean-Jacques Robert
Journal:  J Pediatr       Date:  2007-11-26       Impact factor: 4.406

7.  Glycated albumin is a better indicator for glucose excursion than glycated hemoglobin in type 1 and type 2 diabetes.

Authors:  Kazutomi Yoshiuchi; Munehide Matsuhisa; Naoto Katakami; Yoshihisa Nakatani; Kenya Sakamoto; Takaaki Matsuoka; Yutaka Umayahara; Keisuke Kosugi; Hideaki Kaneto; Yoshimitsu Yamasaki; Masatsugu Hori
Journal:  Endocr J       Date:  2008-04-30       Impact factor: 2.349

8.  Hemoglobin A1c versus oral glucose tolerance test in postpartum diabetes screening.

Authors:  María José Picón; Mora Murri; Araceli Muñoz; José Carlos Fernández-García; Ricardo Gomez-Huelgas; Francisco J Tinahones
Journal:  Diabetes Care       Date:  2012-06-11       Impact factor: 19.112

9.  Nontraditional markers of glycemia: associations with microvascular conditions.

Authors:  Elizabeth Selvin; Lesley M A Francis; Christie M Ballantyne; Ron C Hoogeveen; Josef Coresh; Frederick L Brancati; Michael W Steffes
Journal:  Diabetes Care       Date:  2011-02-18       Impact factor: 19.112

10.  Relationship of glycated albumin to blood glucose and HbA1c values and to retinopathy, nephropathy, and cardiovascular outcomes in the DCCT/EDIC study.

Authors:  David M Nathan; Paula McGee; Michael W Steffes; John M Lachin
Journal:  Diabetes       Date:  2013-08-29       Impact factor: 9.461

View more
  10 in total

1.  Continuous Glucose Monitoring and HbA1c in Cystic Fibrosis: Clinical Correlations and Implications for CFRD Diagnosis.

Authors:  Kevin J Scully; Jordan S Sherwood; Kimberly Martin; Melanie Ruazol; Peter Marchetti; Mary Larkin; Hui Zheng; Gregory S Sawicki; Ahmet Uluer; Isabel Neuringer; Lael M Yonker; Leonard Sicilian; Deborah J Wexler; Melissa S Putman
Journal:  J Clin Endocrinol Metab       Date:  2022-03-24       Impact factor: 5.958

2.  The Relationship Between Continuous Glucose Monitoring and OGTT in Youth and Young Adults With Cystic Fibrosis.

Authors:  Christine L Chan; Laura Pyle; Tim Vigers; Philip S Zeitler; Kristen J Nadeau
Journal:  J Clin Endocrinol Metab       Date:  2022-01-18       Impact factor: 6.134

Review 3.  Overview of Atypical Diabetes.

Authors:  Jaclyn Tamaroff; Marissa Kilberg; Sara E Pinney; Shana McCormack
Journal:  Endocrinol Metab Clin North Am       Date:  2020-10-14       Impact factor: 4.741

4.  Clinical practice versus guidelines for the screening of cystic fibrosis-related diabetes: A French survey from the 47 centers.

Authors:  Laurence Weiss; Olivia Ronsin; Quitterie Reynaud; Michel Abely; Laurent Mely; Pierre-Régis Burgel; Jacques Beltrand; Laurence Kessler
Journal:  J Clin Transl Endocrinol       Date:  2022-04-04

5.  The MEDGICarb-Study: Design of a multi-center randomized controlled trial to determine the differential health-promoting effects of low- and high-glycemic index Mediterranean-style eating patterns.

Authors:  Robert E Bergia; Izabela Biskup; Rosalba Giacco; Giuseppina Costabile; Savanna Gray; Amy Wright; Marilena Vitale; Wayne W Campbell; Rikard Landberg; Gabriele Riccardi
Journal:  Contemp Clin Trials Commun       Date:  2020-08-13

6.  Lessons From Continuous Glucose Monitoring in Youth With Pre-Type 1 Diabetes, Obesity, and Cystic Fibrosis.

Authors:  Christine L Chan; Andrea K Steck; Cameron Severn; Laura Pyle; Marian Rewers; Philip S Zeitler
Journal:  Diabetes Care       Date:  2020-01-14       Impact factor: 19.112

7.  Cystic fibrosis-related diabetes: Prevalence, screening, and diagnosis.

Authors:  Swapnil Khare; Marisa Desimone; Nader Kasim; Christine L Chan
Journal:  J Clin Transl Endocrinol       Date:  2021-12-07

8.  Gestational and pregestational diabetes in pregnant women with cystic fibrosis.

Authors:  Rachael Oxman; Andrea H Roe; Ullal Jagdeesh; Melissa S Putman
Journal:  J Clin Transl Endocrinol       Date:  2021-12-05

Review 9.  Comparison of continuous glucose monitoring to reference standard oral glucose tolerance test for the detection of dysglycemia in cystic Fibrosis: A systematic review.

Authors:  Shanal Kumar; Michael Pallin; Georgia Soldatos; Helena Teede
Journal:  J Clin Transl Endocrinol       Date:  2022-09-27

10.  Exercise Intolerance in Cystic Fibrosis: Importance of Skeletal Muscle.

Authors:  Paula Rodriguez-Miguelez; Nichole Seigler; Haruki Ishii; Reva Crandall; Kathleen T McKie; Caralee Forseen; Ryan A Harris
Journal:  Med Sci Sports Exerc       Date:  2021-04-01
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.